Opinion|Videos|September 27, 2024
Established Multidisciplinary Therapies for SCLC
Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.
Advertisement
Episodes in this series
- What are the conventional therapies that have been used to treat extensive-stage (small cell lung cancer) SCLC and what has their data shown?
a. What are the current unmet needs in extensive-stage settings?
- What are the therapies used for limited-stage SCLC and what is the role of chemoradiotherapy (CRT), and what has the data shown?
a. What are the differences between the schedules of CRT, eg, daily/twice daily/sequential?
- Do you see opportunities in building upon CRT as a standard of care by including systemic therapies, such as immunotherapies, in combination?
Advertisement
Related to this article
The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”
The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
This system-level initiative significantly increased guideline-concordant venous thromboembolism prophylaxis rates in hospitalized patients through coordinated education, clinical decision tools, audit-feedback, and pharmacist integration.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.
Advertisement
Advertisement
Trending on AJMC
1
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC
5